Author

I. Huettner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:proteomics· 3

Frequent Co-Authors

C. Graham· 3 shared J. Seow· 3 shared K. J. Doores· 3 shared M. H. Malim· 2 shared A. C. Hayday· 1 shared A. G. Laing· 1 shared A. Rosa· 1 shared A. Waters· 1 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

C. Graham

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants

J. Seow, C. Graham, S. R. Hallett, T. Lechmere, T. J. A. Maguire, I. Huettner, D. Cox, R. Roberts, A. Waters, C. C. Ward, C. Mant, M. J. Pitcher, J. Spencer, J. Fox, M. H. Malim, K. J. Doores

This study isolates monoclonal antibodies from a vaccinated individual and shows they neutralize multiple SARS-CoV-2 variants effectively.

bioRxiv · Sep 27, 2021Immunology

ADNKA overcomes SARS-CoV2-mediated NK cell inhibition through non-spike antibodies

C. A. Fielding, P. Sabberwal, J. C. Williamson, E. J. Greenwood, E. Crozier, W. Zelek, J. Seow, C. Graham, I. Huettner, J. Edgeworth, B. P. Morgan, K. Ladell, M. Eberl, I. R. Humphreys, B. Merrick, , R. J. Stanton

This study identifies ADNKA as a mechanism by which SARS-CoV-2-infected cells evade NK cell inhibition, showing that non-spike antibodies drive sustained NK activation and cytokine production.

bioRxiv · Apr 6, 2021Immunology

Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike

C. Graham, J. Seow, I. Huettner, H. Khan, N. Kouphou, S. Acors, H. Winstone, S. Pickering, R. Pedro Galao, M. Jose Lista, J. M. Jimenez-Guardeno, A. G. Laing, Y. Wu, M. Joseph, L. Muir, , K. J. Doores

This study examines how mutations in the B.1.1.7 variant of SARS-CoV-2 affect neutralization by monoclonal antibodies targeting non-RBD epitopes.

bioRxiv · Feb 3, 2021 · PreprintImmunology